CiToxLAB Announces the Appointment of Dr. Philippe Ancian as Senior Director
News Jan 14, 2015
CiToxLAB has announced that it has hired Dr. Philippe Ancian as Senior Director of Biomarkers for the group. Philippe has fostered a 20-year career in the development of biomarkers and specialized genomics and proteomics platforms.
Philippe Ancian has a PhD in molecular and cellular biology. He was Head of Biomarkers at Laboratoires Galderma, then Director of Research and Development for the pharma business unit at Protéus before joining CiT in 2005 to develop the functional genomics platform at the Evreux site (France). He then moved to Transgène in 2010 as Senior Director of the Vectorology and Biomarkers departments, to work on strategy definition and to conduct follow-ups on biomarker and immunomonitoring studies in relation to clinical trials from phases I to III.
Since the acquisition of LAB-Research Group by CiT in 2011, CiToxLAB has invested heavily in the development of a suite of platforms for biomarkers analysis. These include functional genomics, flow cytometry immunophenotyping, mass spectrometry, protein and peptide analysis using multiplex techniques, immunohistochemistry, and more recently NGS (Next Generation Sequencing).
CiToxLAB is now a leading player in Europe, having extended its range of services to preclinical and clinical biological samples in the field of transcriptomics and genomics. CiToxLAB experts have analyzed nearly 52,000 Affymetrix chips since 2010.
“I am particularly pleased that Philippe has decided to come back to CiToxLAB after working here between 2005 and 2009. By accelerating its international expansion, the company has more than doubled in size since then.” said Jean-François Le Bigot, Chairman and CEO of the CiToxLAB group. “Philippe will be tasked with developing our biomarkers business, an area where our clients’ needs are growing strongly. We believe that the combination of our platforms, operating in the quality environment of a preclinical CRO (GLP), allied with our biobanking and traceability (LIMS) capabilities; needed for high throughput sample management, provide an opportunity to develop these areas of our business at preclinical and clinical stages; with both existing clients, new companies and institutional clients.”
“Over time, we plan to offer most of the activities associated with biomarkers not just in Europe from our Evreux and Saint-Nazaire (Atlanbio) sites, but also in North America, from our site in Montreal. Therefore, this is a real strategic development and we are confident that Philippe’s scientific, organizational and commercial skills will help him fulfill this mandate,” said Dr Le Bigot.
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
The Exercise Regime of the Future Needs to Check Your GenesNews
Forget protein bars - genes may be central to the exercise regimes of the future, as scientists track down gene changes which occur in response to exercise.READ MORE